Human epidermoid carcinoma cells (A431) over-expressing EGFR.
Alternative Names:
ErbB-2, NEU, NGL, HER2, TKR1, CD340, MLN 19, HER-2/neu
Expression Host : HEK-293 This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Trastuzumab. Clone 4D5-8 recognizes human erbB-2. This product is for research use only. Trastuzumab is a monoclonal antibody targeting HER2, a 185 kDa transmembrane glycoprotein that contains an extracellular domain and intracellular tyrosine kinase activity. When it is functioning normally, the HER2 pathway supports cell growth and division. On the other hand, the over expression of HER2 propels cell growth beyond its typical range. This overexpression is associated with some cancers, namely breast and stomach, in which the HER2 protein can be expressed up to 100 times more than in typical cells. Trastuzumab induces an immune-mediated response that triggers the internalization and downregulation of HER2 making it an excellent target for immunotherapy. Several clinical studies are under way which show that anti-HER-2/neu antibodies inhibit the growth and proliferation of these tumor cells In vitro as well as In vivo.
Clonality:
Monoclonal
Clone Designation:
[4D5-8]
Target:
HER-2/neu
Antibody Type:
Recombinant Antibody
Application Dilute:
The suggested concentration for Trastuzumab biosimilar antibody for staining cells in flow cytometry is <= 1.0 µg per 106 cells in a volume of 100 µl. Titration of the reagent is recommended for optimal performance for each application.
* VAT and and shipping costs not included. Errors and price changes excepted
